Plain-English translation of NCT06261021 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 trial testing , a new medication applied directly to the skin, in adults with discoid lupus erythematosus (a form of lupus that mainly affects the skin). You would apply the medication twice daily to affected areas for 24 weeks. The study will measure whether this treatment is safe and effective at improving skin lesions.
Discoid lupus erythematosus can cause persistent skin damage and scarring, and current treatment options are limited. This medication represents a new approach that researchers hope may be more effective and better tolerated than existing therapies.
You likely qualify if…
You likely don't qualify if…
You will apply the medicated cream to active skin lesions twice per day for 24 weeks (about 6 months). The study uses two different treatment approaches on different areas of skin to compare results — one area will receive the cream without extra covering, and another area will receive the cream with an occlusive dressing at night. You will need to attend study visits so researchers can measure how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Canada